Literature DB >> 18468678

Effects of NPY and the specific Y1 receptor agonist [D-His(26)]-NPY on the deficit in brain reward function and somatic signs associated with nicotine withdrawal in rats.

Daria Rylkova1, Jeffrey Boissoneault, Shani Isaac, Melissa Prado, Hina P Shah, Adrie W Bruijnzeel.   

Abstract

Tobacco addiction is a chronic disorder that is characterized by dysphoria upon smoking cessation and relapse after periods of abstinence. Previous research suggests that Neuropeptide Y (NPY) and Y1 receptor agonists attenuate negative affective states and somatic withdrawal signs. The aim of the present experiments was to investigate the effects of NPY and the specific Y1 receptor agonist [D-His(26)]-NPY on the deficit in brain reward function and somatic signs associated with nicotine withdrawal in rats. The intracranial self-stimulation procedure was used to assess the effects of nicotine withdrawal on brain reward function as this procedure can provide a quantitative measure of emotional states in rodents. Elevations in brain reward thresholds are indicative of a deficit in brain reward function. In the first experiment, NPY did not prevent the elevations in brain reward thresholds associated with precipitated nicotine withdrawal and elevated the brain reward thresholds of the saline-treated control rats. Similar to NPY, [D-His(26)]-NPY did not prevent the elevations in brain reward thresholds associated with precipitated nicotine withdrawal and elevated the brain reward thresholds of the saline-treated control rats. Neither NPY nor [D-His(26)]-NPY affected the response latencies. In a separate experiment, it was demonstrated that the specific Y1 receptor antagonist BIBP-3226 prevented the NPY-induced elevations in brain reward thresholds. NPY attenuated the overall somatic signs associated with precipitated nicotine withdrawal. [D-His(26)]-NPY did not affect the overall somatic signs associated with precipitated nicotine withdrawal, but decreased the number of abdominal constrictions. Both NPY and [D-His(26)]-NPY attenuated the overall somatic signs associated with spontaneous nicotine withdrawal. These findings indicate that NPY and [D-His(26)]-NPY attenuate somatic nicotine withdrawal signs, but do not prevent the deficit in brain reward function associated with precipitated nicotine withdrawal. In addition, NPY decreases the sensitivity to rewarding electrical stimuli via an Y1 dependent mechanism.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18468678      PMCID: PMC2435593          DOI: 10.1016/j.npep.2008.03.004

Source DB:  PubMed          Journal:  Neuropeptides        ISSN: 0143-4179            Impact factor:   3.286


  49 in total

Review 1.  Addiction and the brain: the neurobiology of compulsion and its persistence.

Authors:  S E Hyman; R C Malenka
Journal:  Nat Rev Neurosci       Date:  2001-10       Impact factor: 34.870

2.  Neuropeptide-Y exerts antidepressant-like effects in the forced swim test in rats.

Authors:  K A Stogner; P V Holmes
Journal:  Eur J Pharmacol       Date:  2000-01-10       Impact factor: 4.432

3.  Dramatic decreases in brain reward function during nicotine withdrawal.

Authors:  M P Epping-Jordan; S S Watkins; G F Koob; A Markou
Journal:  Nature       Date:  1998-05-07       Impact factor: 49.962

4.  Fluoxetine combined with a serotonin-1A receptor antagonist reversed reward deficits observed during nicotine and amphetamine withdrawal in rats.

Authors:  A A Harrison; Y T Liem; A Markou
Journal:  Neuropsychopharmacology       Date:  2001-07       Impact factor: 7.853

Review 5.  Neuroadaptive responses in brainstem noradrenergic nuclei following chronic morphine exposure.

Authors:  E J Van Bockstaele; A S Menko; G Drolet
Journal:  Mol Neurobiol       Date:  2001 Apr-Jun       Impact factor: 5.590

6.  Identification of potent and selective neuropeptide Y Y(1) receptor agonists with orexigenic activity in vivo.

Authors:  D Mullins; D Kirby; J Hwa; M Guzzi; J Rivier; E Parker
Journal:  Mol Pharmacol       Date:  2001-09       Impact factor: 4.436

7.  The neuropeptide Y (NPY) Y1 receptor subtype mediates NPY-induced antidepressant-like activity in the mouse forced swimming test.

Authors:  John P Redrobe; Yvan Dumont; Alain Fournier; Rémi Quirion
Journal:  Neuropsychopharmacology       Date:  2002-05       Impact factor: 7.853

8.  Inhibitory effect of neuropeptide Y on morphine withdrawal is accompanied by reduced c-fos expression in specific brain regions.

Authors:  T R Clausen; M Møller; D P Woldbye
Journal:  J Neurosci Res       Date:  2001-05-15       Impact factor: 4.164

9.  The rewarding properties of neuropeptide Y in perifornical hypothalamus vs. nucleus accumbens.

Authors:  C M Brown; D V Coscina; P J Fletcher
Journal:  Peptides       Date:  2000-08       Impact factor: 3.750

10.  Pharmacological characterization of the selective nonpeptide neuropeptide Y Y1 receptor antagonist BIBP 3226.

Authors:  H N Doods; W Wienen; M Entzeroth; K Rudolf; W Eberlein; W Engel; H A Wieland
Journal:  J Pharmacol Exp Ther       Date:  1995-10       Impact factor: 4.030

View more
  15 in total

Review 1.  Tobacco addiction and the dysregulation of brain stress systems.

Authors:  Adrie W Bruijnzeel
Journal:  Neurosci Biobehav Rev       Date:  2012-03-03       Impact factor: 8.989

2.  Effects of a selective Y2R antagonist, JNJ-31020028, on nicotine abstinence-related social anxiety-like behavior, neuropeptide Y and corticotropin releasing factor mRNA levels in the novelty-seeking phenotype.

Authors:  Cigdem Aydin; Ozge Oztan; Ceylan Isgor
Journal:  Behav Brain Res       Date:  2011-04-08       Impact factor: 3.332

3.  Both GABA(B) receptor activation and blockade exacerbated anhedonic aspects of nicotine withdrawal in rats.

Authors:  Styliani Vlachou; Neil E Paterson; Sebastien Guery; Klemens Kaupmann; Wolfgang Froestl; Deboshri Banerjee; M G Finn; Athina Markou
Journal:  Eur J Pharmacol       Date:  2011-01-22       Impact factor: 4.432

Review 4.  Antireward, compulsivity, and addiction: seminal contributions of Dr. Athina Markou to motivational dysregulation in addiction.

Authors:  George F Koob
Journal:  Psychopharmacology (Berl)       Date:  2017-01-03       Impact factor: 4.530

Review 5.  Neuropeptide Y and posttraumatic stress disorder.

Authors:  R Sah; T D Geracioti
Journal:  Mol Psychiatry       Date:  2012-07-17       Impact factor: 15.992

6.  Preadolescent tobacco smoke exposure leads to acute nicotine dependence but does not affect the rewarding effects of nicotine or nicotine withdrawal in adulthood in rats.

Authors:  Hidetaka Yamada; Mahendra Bishnoi; Kim F M Keijzers; Irma A van Tuijl; Elysia Small; Hina P Shah; Rayna M Bauzo; Firas H Kobeissy; Sreedharan N Sabarinath; Hartmut Derendorf; Adrie W Bruijnzeel
Journal:  Pharmacol Biochem Behav       Date:  2010-03-06       Impact factor: 3.533

7.  Vulnerability to nicotine abstinence-related social anxiety-like behavior: molecular correlates in neuropeptide Y, Y2 receptor and corticotropin releasing factor.

Authors:  Cigdem Aydin; Ozge Oztan; Ceylan Isgor
Journal:  Neurosci Lett       Date:  2010-12-30       Impact factor: 3.046

8.  Chronic treatment with the vasopressin 1b receptor antagonist SSR149415 prevents the dysphoria associated with nicotine withdrawal in rats.

Authors:  Xiaoli Qi; Lidia Guzhva; Yue Ji; Adriaan W Bruijnzeel
Journal:  Behav Brain Res       Date:  2015-06-22       Impact factor: 3.332

9.  Tobacco smoke exposure induces nicotine dependence in rats.

Authors:  Elysia Small; Hina P Shah; Jake J Davenport; Jacqueline E Geier; Kate R Yavarovich; Hidetaka Yamada; Sreedharan N Sabarinath; Hartmut Derendorf; James R Pauly; Mark S Gold; Adrie W Bruijnzeel
Journal:  Psychopharmacology (Berl)       Date:  2009-11-21       Impact factor: 4.530

Review 10.  kappa-Opioid receptor signaling and brain reward function.

Authors:  Adrie W Bruijnzeel
Journal:  Brain Res Rev       Date:  2009-10-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.